Raptiva (efalizumab) sales are now suspended in Canada due to the risk of fatal opportunistic infections

Raptiva (efalizumab) sales are now suspended in Canada due to the risk of fatal opportunistic infections.

Several long-term users developed progressive multifocal leukoencephalopathy (PML)...a usually fatal brain infection that's seen in patients with severe immunosuppression.

Raptiva will be removed from the market if a Health Canada investigation finds that the risks outweigh the benefit.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote